Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- CSIMC Recommends NHI Price Listing for 8 APIs/10 Products Including Xalkori, Poteligeo
May 24, 2012
- Working Group to Set Specific Targets for 5-Year Clinical Research/Trial Activation Plan
May 22, 2012
- 1st Committee to Discuss 5 Items Including Add’l Indication of Fibromyalgia for Lyrica on June 1
May 22, 2012
- Gov’t to Form 3 Strategic Councils for Science & Technology Policy, with Its 1st Meeting for Medical Care on May 25
May 22, 2012
- 2nd Committee on New Drugs to Discuss Approval for 4 Items Including Pfizer Japan’s RCC Treatment Axitinib
May 21, 2012
- MHLW, Daiichi Sankyo Call for Proper Use of Denosumab after 3 Deaths in US
May 21, 2012
- DPJ Committee Approves Proposal to Reform Preventive Vaccination System
May 18, 2012
- DPJ Subcommittee Proposes Inclusion of 3 Subsidized Vaccines in Regular Vaccination Programs
May 16, 2012
- Gov’t to Begin Operating “Drug Discovery Network” This FY with Initial Focus on Seeds for Anticancer Agents
May 14, 2012
- DPJ’s PAL Subcommittee Calls for Establishment of Third-Party Organization within MHLW
May 11, 2012
- Expert Subcommittee on Cost-Effectiveness Assessments to Begin Discussions this Month: Policy Planning Director Sakoi
May 11, 2012
- Japan’s Application for Membership in PIC/S Reported: PIC/S General Meeting
May 11, 2012
- Risk Management Plans Must Be Submitted By 1 Month Prior to Launch: MHLW Notification
May 8, 2012
- Gov’t, Industry Leaders to Meet on May 10 for Second Dialogue on 5-Year Medical Innovation Strategy
May 8, 2012
- MHLW to Ease GCP Ordinance in Line with ICH-GCP, Promote Clinical Trials
May 7, 2012
- 1st Committee on Drugs Recommends Approval for MTPC’s DPP-4 Inhibitor Teneligliptin
May 7, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (1)
May 1, 2012
- DPJ's PAL Subcommittee to Finalize Reform Proposal in May, Some Recommendations to Be Reflected in Economy Revival Strategy
April 27, 2012
- CSIMC to Establish Expert Subcommittee on Cost-Effective Assessments, 1st Meeting Scheduled in June
April 26, 2012
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…